David Benjamin

Comment Precision medicine in genitourinary oncology: are we pivoting towards imprecision? David J. Benjamin, Corresponding Author David J. Benjamin Hoag Family Cancer Institute, Newport Beach, CA, USA Correspondence: David J. Benjamin, Hoag Family Cancer Institute, 1 Hoag Drive, Building 41, Newport Beach, CA 92663, USA.

Comment Monitoring and reporting sexual health adverse events for genitourinary cancer therapies David J. Benjamin, Corresponding Author David J. Benjamin Hoag Family Cancer Institute, Newport Beach, CA, USA Correspondence: David J. Benjamin, Hoag Family Cancer Institute, 1 Hoag Drive, Building 41, Newport Beach, CA 92663, USA. e-mail: david.benjamin@hoag.org Search for more papers by this authorCharles A. Loeb, Charles A.

1 INTRODUCTION The incidence of testicular cancer has been rising globally among young adult men for the past five decades for reasons not currently well-understood.1 Although a rare genitourinary malignancy that is generally curable, testicular cancer remains a significant public health concern due to long-term medical, psychological and social burden associated with treatment and its short- and long-term toxicities.2 Risk factors leading to the development of testicular cancer include age,...